234 related articles for article (PubMed ID: 16222309)
41. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.
Smith MR; Cook RJ; Coleman R; Brown J; Lipton A; Major P; Hei YJ; Saad F
Urology; 2007 Aug; 70(2):315-9. PubMed ID: 17826496
[TBL] [Abstract][Full Text] [Related]
42. Bisphosphonate and low-dose dexamethasone treatment for patients with hormone-refractory prostate cancer.
Ueda T; Suzuki H; Akakura K; Ishihara M; Kamiya N; Komiya A; Shimbo M; Suyama T; Sakamoto S; Ichikawa T
Hinyokika Kiyo; 2006 Jul; 52(7):515-21. PubMed ID: 16910582
[TBL] [Abstract][Full Text] [Related]
43. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
Saad F; McKiernan J; Eastham J
Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
[TBL] [Abstract][Full Text] [Related]
44. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
45. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
46. [Relationship of neuroendocrine differentiation to biological behavior of prostate cancer].
Wu XL; Huang KT; Chen W; Chen L; Dong L; Yu ZX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):472-5. PubMed ID: 19567097
[TBL] [Abstract][Full Text] [Related]
47. The cost of treating skeletal-related events in patients with prostate cancer.
Lage MJ; Barber BL; Harrison DJ; Jun S
Am J Manag Care; 2008 May; 14(5):317-22. PubMed ID: 18471035
[TBL] [Abstract][Full Text] [Related]
48. Serum thyroid-stimulating hormone is elevated in men with Gleason 8 prostate cancer.
Lehrer S; Diamond EJ; Stone NN; Stock RG
BJU Int; 2005 Aug; 96(3):328-9. PubMed ID: 16042724
[TBL] [Abstract][Full Text] [Related]
49. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
Krejcarek SC; Chen MH; Renshaw AA; Loffredo M; Sussman B; D'Amico AV
Urology; 2007 Mar; 69(3):515-9. PubMed ID: 17382156
[TBL] [Abstract][Full Text] [Related]
50. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
[TBL] [Abstract][Full Text] [Related]
51. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
[TBL] [Abstract][Full Text] [Related]
52. [Role of biochemical indices as metastatic markers in patients with prostatic cancer invading skeleton].
Liubimova NV; Trapeznikova MF; Robins SP; Ognerubov SA; Kushlinskiĭ NE
Urologiia; 2000; (4):15-9. PubMed ID: 11186686
[TBL] [Abstract][Full Text] [Related]
53. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006.
Sathiakumar N; Delzell E; Morrisey MA; Falkson C; Yong M; Chia V; Blackburn J; Arora T; Kilgore ML
Prostate Cancer Prostatic Dis; 2011 Jun; 14(2):177-83. PubMed ID: 21403668
[TBL] [Abstract][Full Text] [Related]
54. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.
Shah RB; Mehra R; Chinnaiyan AM; Shen R; Ghosh D; Zhou M; Macvicar GR; Varambally S; Harwood J; Bismar TA; Kim R; Rubin MA; Pienta KJ
Cancer Res; 2004 Dec; 64(24):9209-16. PubMed ID: 15604294
[TBL] [Abstract][Full Text] [Related]
55. Biochemical markers and skeletal metastases.
Demers LM; Costa L; Lipton A
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S138-47. PubMed ID: 14600604
[TBL] [Abstract][Full Text] [Related]
56. [The effects of clodronate for the pain treatment of bone metastasis due to prostate cancer].
Ozyuvaci E; Altan A; Demir C
Agri; 2005 Jan; 17(1):49-53. PubMed ID: 15791501
[TBL] [Abstract][Full Text] [Related]
57. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption.
Percival RC; Urwin GH; Harris S; Yates AJ; Williams JL; Beneton M; Kanis JA
Eur J Surg Oncol; 1987 Feb; 13(1):41-9. PubMed ID: 3102281
[TBL] [Abstract][Full Text] [Related]
58. Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data.
Mountzios G; Ramfidis V; Terpos E; Syrigos KN
Clin Lung Cancer; 2011 Nov; 12(6):341-9. PubMed ID: 21703936
[TBL] [Abstract][Full Text] [Related]
59. The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease.
Pecherstorfer M; Zimmer-Roth I; Schilling T; Woitge HW; Schmidt H; Baumgartner G; Thiébaud D; Ludwig H; Seibel MJ
J Clin Endocrinol Metab; 1995 Jan; 80(1):97-103. PubMed ID: 7829646
[TBL] [Abstract][Full Text] [Related]
60. Diagnostic value of bone and tumour markers in patients with malignant diseases.
Oremek GM; Weis A; Sapoutzis N; Sauer-Eppel H
Anticancer Res; 2003; 23(2A):987-90. PubMed ID: 12820336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
